Lupin plans to build a new pharmaceutical manufacturing plant in Florida, U.S., with a $250 million investment over a five-year period.
The site, in Coral Springs, will produce 25 critical respiratory medicines, the generic drugmaker said on Wednesday becoming the first Indian pharma firm to unveil manufacturing plans in the U.S. since President Donald Trump’s September 25 announcement proposing 100% tariff on import of branded and patented pharmaceutical products. He, however, had said that the levy will not apply to companies manufacturing in the U.S.
The new facility is a core part of the growth strategy and build on the company’s existing presence in Florida, which is home to Lupin’s Advanced Inhalation Research Center and its U.S. headquarters. “The investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability — and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients,” Chief Technical Operations Officer Christoph Funke said.
The $250 million is the cumulative projected investment and include those on research and development, infrastructure and capital expenditure. Among the products, the plant will make lifesaving albuterol inhalers for children with asthma. It will cater to the U.S and markets abroad, the company said, describing the plan as part of its long standing commitment to America’s patients and healthcare system.
“By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen Lupin’s position as a global respiratory leader. This will generate over 200 new long-term, skilled jobs by 2030 in Broward County,” the company said.
The Coral Springs facility will anchor U.S. production of critical respiratory therapies, diversify the supply chain and ensure affordable, reliable access — from routine pediatric care to pandemic-scale demand. Lupin said it has acquired more than 5 acres to embark on the 70,000 square feet facility. Lupin will receive tax credits and incentives from Florida.
Lupin has 15 manufacturing facilities spread across India, the U.S., Brazil and Mexico. In the U.S. it commenced operations in 2006. About ten years later, through an acqusition, Lupin got its first manufacturing facility in the U.S., in New Jersey.
According to reports, though the U.S. President had set October 1 as the date from which the 100% tariff will become effective, the country’s administration will take more time to implement the levy. There is not much clarity on whether the tariff will apply to branded generics, which many Indian pharma firms market, too. Some pharma companies like Natco Pharma had been talking about the importance of having manufacturing foothold in the U.S.
Published – October 08, 2025 09:19 pm IST
